

Most recent articles on methotrexate in breast cancer

Source: <http://sci.tech-archive.net/Archive/sci.med.diseases.cancer/2009-03/msg00014.html>

- *From:* scimedweb@xxxxxxxxx
 - *Date:* Sun, 8 Mar 2009 04:21:02 -0700 (PDT)
-

Most recent articles on methotrexate in breast cancer:

HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.

Zhu L, Li YF, Chen WG, He JR, Peng CH, Zhu ZG, Li HW.
Chin Med J (Engl). 2008 Oct 20;121(20):1965-8.

Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer.

Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN.
Clin Breast Cancer. 2008 Dec;8(6):516-21.

Maintenance treatment in metastatic breast cancer.

Sánchez-Muñoz A, Pérez-Ruiz E, Ribelles N, Márquez A, Alba E.
Expert Rev Anticancer Ther. 2008 Dec;8(12):1907-12.

Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer.

García-Sáenz JA, Martín M, Calles A, Bueno C, Rodríguez L, Bobokova J, Custodio A, Casado A, Díaz-Rubio E.
J Chemother. 2008 Oct;20(5):632-9.

Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.

Stemmler HJ, Mengerle K, Schmitt M, Harbeck N, Laessig D, Herrmann KA, Schaffer P, Heinemann V.
Anticancer Drugs. 2008 Sep;19(8):832-6.

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.

Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilas G.

Most recent articles on methotrexate in breast cancer

Cancer Invest. 2008 Jun;26(5):491–8.

Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.

Dobrzanski MJ, Reome JB, Hyland JC, Rewers-Felkins KA, Abulsamad K, Adams SL.

Clin Immunol. 2008 Aug;128(2):205–18.

DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients.

Ejlertsen B, Jensen MB, Mouridsen HT, Andersen J, Cold S, Jakobsen E, Kamby C, Sørensen PG, Ewertz M.

Acta Oncol. 2008;47(4):709–17.

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premenopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.

E